Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

American Journal of Health-System Pharmacy

Volumn 69, Issue 21, 2012, Pages 1863-1870

  Labreche, Matthew J ^a   Frei, Christopher R ^b,c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UTHSC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BLOODSTREAM INFECTION; CYSTIC FIBROSIS; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION;

EID: 84868603184     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110464     Document Type: Review

References (42)

1. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005; 41(suppl 2):S113-9. (Pubitemid 40962481)
2. Fish DN. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. Expert Rev Anti Infect Ther. 2003; 1:371-87. (Pubitemid 38855103)
3. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J Antimicrob Chemother. 1999; 43(suppl B):1-11. (Pubitemid 29231787)
4. Linder JA, Huang ES, Steinman MA et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005; 118:259-68. (Pubitemid 40312637)
5. Frei CR, Labreche MJ, Attridge RT. Fluoroquinolones in community acquired pneumonia: guide to selection and appropriate use. Drugs. 2011; 71:757-70.
6. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother. 2010; 65:1725-32.
7. Defife R, Scheetz MH, Feinglass JM et al. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother. 2009; 53:1074-9.
8. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362:1804-13.
9. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009; 65:414-26.
10. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37:1073-81. (Pubitemid 23141323)
11. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998; 279:125-9. (Pubitemid 28068302)
12. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004; 189:1590-7. (Pubitemid 38648286)
13. Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009; 37:296-305.
14. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S19, vol. 29. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
15. Neuhauser MM, Weinstein RA, Rydman R et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289:885-8. (Pubitemid 37430348)
16. Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003; 37:1643-8. (Pubitemid 37549951)
17. Drusano GL, Johnson DE, Rosen M et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37:483-90. (Pubitemid 23072592)
18. Forrest A, Ballow CH, Nix DE et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993; 37:1065-72. (Pubitemid 23141322)
19. Crandon JL, Kuti JL, Jones RN et al. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009; 43:220-7.
20. Rhomberg PR, Deshpande LM, Kirby JT et al. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis. 2007; 59:425-32. (Pubitemid 350184218)
21. Rhomberg PR, Fritsche TR, Sader HS et al. Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother. 2005; 17:459-69. (Pubitemid 41695592)
22. Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis. 2003; 47:365-72. (Pubitemid 37101171)
23. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002; 22:1216-25. (Pubitemid 35155075)
24. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005; 55:601-7. (Pubitemid 40691835)
25. Guillot E, Sermet I, Ferroni A et al. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy. 2010; 30:1252-8.
26. Payen S, Serreau R, Munck A et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother. 2003; 47:3170-8. (Pubitemid 37229575)
27. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003; 43:698-710. (Pubitemid 36759147)
28. Schaefer HG, Stass H, Wedgwood J et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother. 1996; 40:29-34. (Pubitemid 26019673)
29. Church DA, Kanga JF, Kuhn RJ et al., for the Cystic Fibrosis Study Group. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J. 1997; 16:97-105; discussion, 123-6.
30. Rubio TT, Miles MV, Lettieri JT et al. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J. 1997; 16:112-7; discussion, 123-6.
31. European Society of Clinical Microbiology and Infectious Diseases. The European Committee on Antimicrobial Susceptibility Testing - EUCAST. http://eucast.org (accessed 2012 Mar 18).
32. Jones RN, Farrell DJ, Sader HS. Recent antimicrobial resistance increases among S. pneumoniae in four geographic regions: report from the SENTRY antimicrobial surveillance program. Poster presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). Boston, MA; 2010 Sep 13.
33. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000; 38:151-7.
34. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med. 2001; 111(suppl 9A):13S-18S; discussion 36S-38S.
35. Frei CR, Burgess DS. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy. 2005; 25:1161-7. (Pubitemid 41242575)
36. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1999; 43:79-86. (Pubitemid 29045935)
37. Lacy MK, Lu W, Xu X et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999; 43:672-7. (Pubitemid 29109538)
38. Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001; 45:2793-7. (Pubitemid 32906673)
39. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007; 29:374-9. (Pubitemid 46349590)
40. Cipro (ciprofloxacin hydrochloride) package insert. Wayne, NJ: Bayer Healthcare Pharmaceuticals; 2011 Apr.
41. Levaquin (levofloxacin) package insert. Titusville, NJ: Janssen Pharmaceuticals; 2011 Oct.
42. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement, vol. 31. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.